Pharmacokinetics and tolerability of almorexant in japanese and caucasian healthy male subjects

Pharmacology

Volumn 88, Issue 3-4, 2011, Pages 121-126

  Hoch, Matthias ^a   Hoever, Petra ^a   Alessi, Federica ^b   Marjason, Joanne ^c   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Actelion Pharmaceuticals Italia Srl   (Italy)

^c Q Pharm Pty Ltd   (Australia)

Author keywords

Bridging study; Caucasian; Japanese; Orexin; Pharmacokinetics

Indexed keywords

ALMOREXANT;

ADULT; ANEMIA; ARTICLE; BODY WEIGHT; CAUCASIAN; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG TOLERABILITY; ETHNIC DIFFERENCE; ETHNIC GROUP; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOMNOLENCE;

ACETAMIDES; ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; DIZZINESS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; SLEEP STAGES; YOUNG ADULT;

EID: 80051944001     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000330098     Document Type: Article

References (13)

1. Sakurai T: The neural circuit of orexin (hypocretin): Maintaining sleep and wakefulness. Nat Rev Neurosci 2007; 8: 171-181. (Pubitemid 46294664)
2. Tsujino N, Sakurai T: Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev 2009; 61: 162-176.
3. Spinazzi R, Andreis PG, Rossi GP, Nussdorfer GG: Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacol Rev 2006; 58: 46-57.
4. Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, Hess P, Qiu C, Buchmann S, Scherz M, Weller T, Fischli W, Clozel M, Jenck F: Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007; 13: 150-155.
5. Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J, Dingemanse J: Orexin receptor antagonism, a new sleeppromoting paradigm: an ascending singledose study with almorexant. Clin Pharmacol Ther 2010; 87: 593-600.
6. Bjornsson TD, Wagner JA, Donahue SR, Harper D, Karim A, Khouri MS, Murphy WR, Roman K, Schneck D, Sonnichsen DS, Stalker DJ, Wise SD, Dombey S, Loew C: A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 2003; 43: 943-967. (Pubitemid 37022739)
7. Kim K, Johnson JA, Derendorf H: Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004; 44: 1083-1105. (Pubitemid 39202454)
8. Wood AJ, Zhou HH: Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20: 350-373.
9. Xie HG, Kim RB, Wood AJ, Stein CM: Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-850. (Pubitemid 32385908)
10. Hoch M, Hoever P, Haschke M, Krahenbuhl S, Dingemanse J: Food effect and biocomparison of two formulations of the dual orexin receptor antagonist almorexant in healthy male subjects. J Clin Pharmacol 2011; 51: 1116-1121.
11. Dang MT, Hambleton J, Kayser SR: The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005; 39: 1008-1012. (Pubitemid 40695964)
12. Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J: Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 2004; 19: 83-95.
13. Kalliokoski A, Niemi M: Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705.